Author:
Rivera-Tenorio Ayleen,Hernández-Díaz Hector,Triana Pablo Andrés,Gutiérrez- Posso Juliana,Osorio-Gómez Ana María,Saez Velandia Julio Ernesto,Salazar Acosta William,Portillo-Miño Jose Darío
Abstract
Case description:A 22-year-old female patient received the first dose of Pfizer-BioNTech vaccine (RNAm) against COVID-19; 6 days later, she presented abdominal pain located in the right hypochondrium and epigastrium, associated with emetic episodes. Consultation 21 days later due to the same symptoms; three days after the seconddose of the vaccine was administered.
Clinical findings:Pain on palpation in the right hypochondrium. Laboratories reported hepatocellular lesions and cholestasis, with negative amylase, hepatotropic virus and autoimmune hepatitis tests. Liver and biliary tract ultrasound and cholangioresonance were normal.
Treatment and Results:Hyoscine and intravenous fluids as support therapy. She presented improvement in abdominal pain and a progressive decrease of transaminases and bilirubin levels until normalization and was discharged on the fifth day of hospitalization. A drug-associated hepatotoxicity (DILI) diagnosis was considered probable, in this case, secondary to vaccination against COVID-19.
Clinical Relevance:The current SARS-CoV-2 pandemic has spurred the development of new vaccines, the safety of which remains a concern. There is a likely causal relationship between vaccination and liver involvement in this clinical case rather than simply a sporadic occurrence.
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献